Granules Pharmaceuticals Secures USFDA EIR for Chantilly Manufacturing Facility
Granules India Limited has announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, USA, has successfully received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA).
The facility received a Voluntary Action Indicated (VAI) classification following a regulatory inspection conducted by the USFDA from March 30 to April 3, 2026.
This development marks another important milestone for Granules India as it continues to strengthen its commitment to quality manufacturing, regulatory compliance, and patient safety across its global operations.
USFDA Inspection Details
The USFDA inspection at the Chantilly facility took place over five days, from March 30 to April 3, 2026. During the inspection, regulators issued four observations under Form 483.
Following the company’s response and corrective actions, the USFDA issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status.
Inspection Summary
| Particulars | Details |
|---|---|
| Company | Granules Pharmaceuticals, Inc. |
| Parent Company | Granules India Limited |
| Facility Location | Chantilly, Virginia, USA |
| Inspection Period | March 30 – April 3, 2026 |
| Form 483 Observations | 4 |
| Final Classification | Voluntary Action Indicated (VAI) |
| Regulatory Authority | USFDA |
What Does VAI Classification Mean?
A Voluntary Action Indicated (VAI) classification means that the USFDA identified certain observations during the inspection that require attention, but the issues are not severe enough to warrant regulatory enforcement action.
Under a VAI classification:
- The facility remains operational.
- No warning letter is automatically issued.
- The company is expected to voluntarily address the observations.
- The facility continues to supply products while maintaining compliance efforts.
The issuance of the EIR indicates the inspection process has been formally concluded by the USFDA.
Importance of the Chantilly Facility
The Chantilly facility plays a significant role in Granules’ global manufacturing and supply chain network. It supports the company’s operations in regulated markets, including the United States.
The facility contributes to:
- Pharmaceutical manufacturing operations
- Quality assurance and compliance activities
- Supply chain continuity
- Product availability for patients
Maintaining regulatory compliance at this facility is essential for supporting Granules’ long-term growth strategy in international markets.
Granules India Reaffirms Commitment to Quality
Following the receipt of the EIR, Granules reiterated its commitment to maintaining the highest standards of:
- Product quality
- Regulatory compliance
- Manufacturing excellence
- Patient safety
- Continuous improvement
The company stated that quality systems and compliance remain key priorities across all its manufacturing facilities in both India and the United States.
Impact on Granules India
The successful closure of the USFDA inspection process is viewed as a positive development for Granules India. Regulatory compliance remains a critical factor for pharmaceutical companies operating in highly regulated markets such as the United States.
The receipt of the EIR demonstrates the company’s ongoing efforts to strengthen operational controls and maintain compliance with global regulatory standards.
Conclusion
Granules Pharmaceuticals, Inc. has received the USFDA Establishment Inspection Report (EIR) for its Chantilly, Virginia facility with a Voluntary Action Indicated (VAI) classification following an inspection conducted in March-April 2026. The outcome reflects the company’s continued focus on quality systems, compliance, and patient safety while supporting its global manufacturing operations.
As Granules India continues to expand its presence in regulated markets, maintaining strong regulatory compliance remains a cornerstone of its business strategy.
Keywords:
Granules Pharmaceuticals USFDA EIR, Granules India USFDA Inspection 2026, Chantilly Facility VAI Classification, Granules Pharmaceuticals FDA Update, Granules India News, USFDA EIR Meaning, Pharmaceutical Regulatory News, Granules India Stock News
Recommended Products
